medigraphic.com
ISSN 2448-8909 (Print)

2017, Number 2

<< Back Next >>

Med Crit 2017; 31 (2)

Relationship between chronic beta-blockers usage and mortality in sepsis and septic shock

Espinoza VMV, Martínez ZR, Zaragoza GJJ

Language: Spanish
References: 15
Page: 74-77
PDF size: 182.93 Kb.


ABSTRACT

It has been considered that beta-blockers are used to reduce adrenergic overstimulation in septic patients. Therefore, we designed a case-control study to identify if chronic use of beta-blockers is related to less 30-day mortality among septic patients. We review medical records of ICU admission. In total, we included 104 patients divided into two groups: beta-blockers (n = 16) and control (n = 88). Patients in the study group showed no difference in mortality relative to control (p = 0.99), however the cardiovascular SOFA was higher (p = 0.05), required higher dose of vasopressors (p = 0.18) and longer stay in UTI (p = 0.11). The chronic use of beta-blockers was not protective factor for mortality in septic patients.


REFERENCES

  1. Sanfilippo F, Santonocito C, Foëx P. Use of beta-blockers in non-cardiac surgery: an open debate. Minerva Anestesiol. 2014;80(4):482-494.

  2. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med. 1996;335(23):1713-1720.

  3. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;341(24):1789-1794.

  4. POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371(9627):1839-1847.

  5. Novotny NM, Lahm T, Markel TA, Crisostomo PR, Wang M, Wang Y, et al. beta-Blockers in sepsis: reexamining the evidence. Shock. 2009;31(2):113-119.

  6. Stoelting RK, Hilller SC. Alpha and beta-adrenergic receptor antagonists. In: Pharmacology & Physiology in Anesthetic Practice. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006. p. 321-337.

  7. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310(16):1683-1691.

  8. Ginsberg F. β-blockers: more good news? Crit Care Med. 2012;40(10):2901-2902.

  9. Hamzaoui O, Teboul JL. The role of beta-blockers in septic patients. Minerva Anestesiol. 2015;81(3):312-319.

  10. Dinarello CA, Abraham E. Does blocking cytokines in sepsis work? Am J Respir Crit Care Med. 2002;166(9):1156-1157.

  11. Oberbeck R, van Griensven M, Nickel E, Tschernig T, Wittwer T, Pape HC. Influence of beta-adrenoceptor antagonists on hemorrhage-induced cellular immune suppression. Shock. 2002;18(4):331-335.

  12. Rudiger A. Beta-block the septic heart. Crit Care Med. 2010;38(10 Suppl):S608-S612.

  13. Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. 2008;36(6):1701-1706.

  14. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med. 1995;333(16):1025-1032.

  15. Morelli A, Singer M, Ranieri VM, D’Egidio A, Mascia L, Orecchioni A, et al. Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. Intensive Care Med. 2016;42(10):1528-1534.




2020     |     www.medigraphic.com